Impavido

Drug Industry’s VIP Pass Costs $125 Million and Climbing
Bloomberg
Tue, 01/6/15 - 09:11 am
priority review
FDA
Knight Therapeutics
Impavido
FDA panel backs Paladin Labs' parasitic disease drug
Reuters
Fri, 10/18/13 - 05:48 pm
FDA
advisory panels
Paladin
leishmaniasis
Impavido